In this episode of Px Pulse. we take a look the results of the ECHO study and what they mean from several angles. Leaders of the trial, formally called Evidence for Contraceptive options in HIV Outcomes, announced study findings in mid-June. ECHO found no substantial difference in HIV acquisition among women using one of three highly effective contraceptive methods in the study: DMPA-IM, the copper IUD, the LNG implant).
The ECHO Trial Results: Time to Act
Understanding the Results of the ECHO Study
A comprehensive guide to interpreting the results of the ECHO Study. Includes concise information on the study’s background, design and results, and a full section on next steps such as the WHO process for updating its guidance and what advocates can do to get involved.
A Roadmap for Results: Understanding the ECHO Study Results
On June 13, FP2020 and AVAC held a webinar, A Roadmap for Results: Understanding the ECHO Study Results, with the ECHO team following the results announcement. The webinar explained the trial, provided topline results, outlined next steps, and offered key advocacy messages to help all stakeholders understand the findings.
Watch here.
The ECHO Trial: Preparing for action
In this episode of Px Pulse, AVAC spoke with two leaders from the ECHO trial team, Dr. Jared Baeten and Dr. Helen Rees, to understand what the trial can and cannot tell us. And you’ll hear leading women’s advocates from several countries where the ECHO trial took place share their demands. Carry what you learn forward as the ECHO trial raises the volume on an urgent conversation—how to empower African women around their sexual and reproductive health.
Hormonal Contraception and HIV Risk: Understanding the ECHO trial
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is an open-label, randomized, clinical trial comparing three highly effective, reversible methods of contraception — the progestogen-only injectable depot-medroxyprogesterone acetate (DMPA), a levonorgestrel implant, and the non-hormonal copper intrauterine device — to evaluate whether there is any difference in the risk of acquiring HIV infection among users of these methods.
Results, expected in mid-2019, will help guide the implementation of safe, effective policies and services that will enable women at high risk of HIV to make fully informed choices about contraception and HIV prevention.
The webinar featured:
Beth Schlachter, Executive Director, FP2020
Dr. Jared Baeten, Vice Chair, Department of Global Health, University of Washington, ECHO Consortium
Dr. Nelly Mugo, Research Associate Professor, Global Health, University of Washington, ECHO Management Committee
Tamar Abrams, Communications Director, FP2020
You may view the webinar here.
HIV Vaccine Research and Development Pipeline: 2019 Supplement
A slide deck overview of what’s happening in HIV vaccine research now.
Vaccine Strategies in the Pipeline
Scientists are studying these strategies to develop an effective vaccines and deliver it into the body in a way that maximizes the immune response.
HIV-Specific Neutralizing Antibodies – Targets and research status
Numerous studies, both early and late phase, are investigating the efficacy of neutralizing antibodies. This infographic shows the ongoing studies and the differing locations they target on the virus.
Total Vaccine Spending by Area
A look at the percentage of total funds invested in different aspects of vaccine research.
Vaccines Trial Participation in 2019
A look at the number of participants in vaccines trials in 2019 according to trial phase.